A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants

Phase 1 Completed 31 enrolled Janssen Research & Development, LLC

RandomizedSequentialDouble-blindOther

Summary

The purpose of the study is to assess the safety and tolerability of JNJ-72537634 compared with placebo in healthy participants after administration of single and multiple day doses.

Timeline

Start: 2019-04-30
Primary completion: 2020-02-10
Completion: 2020-02-10

Publications

Silber JL, Norman JM, Kanno T, Crossette EM, Szabady R, Menon R, Marko M, Hao LY, Tomsho L, Bhagat S, Yuan A, Olle B, Lamouse-Smith E. A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adults. Eur J Gastroenterol Hepatol. 2026 Apr 1;38(4):437-441. doi: 10.1097/MEG.0000000000003098. Epub 2025 Oct 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-72537634	Unknown	1e+09 unknown	Oral
Subject	JNJ-72537634	Unknown	1e+10 unknown	Oral

Indications

No indication recorded.